I think we can agree that redeeming the notes is the most important thing to shareholders and pps at this point. I also think that management is realizing that if they are to keep this company going and be able to attract new investors they are going to have to put more focus on the pps and not assume it will take care of itself. From what I have seen they are beginning to do that.
The point I have been trying to make is that they have come through with what they said they were going to do so far. The only thing that has not stayed true was the timelines. The pre clinical data is coming in and it has all been strong.
I don't think it was an accident that the very first thing listed in the 2018 Outlook, in the management comment section, is redeeming the notes. They get it. It is simply a matter of obtaining the funds. My hope here is that they have continued to get investors for the C class preferred shares and that once enough has been reached they pay off the original note for Eagle, to start.
As far as the dilution as it is today. I have heard people suggest "why dilute now, why not wait until its at a higher price". Endonovo has no choice on when Eagle chooses to convert. Period. That contract has already been set in place. The only way out is a buyout of the note. To anyone who would say why did they take the note in the first place. How would they have funded their pre clinical trials? Before Eagle provided funds to Endonovo they had no provable data. This note gave them the opportunity to show that their device works. The fact that they stipulated a daily limit is the reason we are not in trips right now. They did the best they could with where they were at at the time. Now times have changed and the financing will as well.
When the PR hits and the realization that ENDV is no longer diluting sinks in this is going to fly. Dilution is the daily topic. People pop in on the board with "still diluting I see comments" all the time. Take that away and no short will stop this.
These guys have not taken a paycheck for years. Mann spent over $100k of his own money on common shares last year. They don't just need to make this happen for us, they need to make it happen for themselves.
News 
Market Data 
Discover 
